Faron
Pharmaceuticals Oy
("Faron
or the "Company")
Decisions
of the Board of Directors
Company announcement, April 8, 2024
at 9:05 (EEST) / 7:05 AM (GMT) / 12:05 AM (EDT)
TURKU, FINLAND / BOSTON,
MA - The annual general meeting ("AGM") of
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took
place on April 5, 2024 and after the AGM, the Board of
Directors ("Board") convened.
Frank Armstrong and Erik Ostrowsi
did not stand for re-election and thus their tenure in the Company
Board of Directors ended at the end of the AGM on 5 April,
2024.
At the meeting of the Board held
following the AGM, Tuomo Pätsi was elected as the Chair of the
Board.
In addition, the Board elected the
Chairs and other members to the Board committees from among its
members as follows:
·
Markku Jalkanen was elected the Chair of the Audit
Committee and Marie-Louise Fjällskog and John Poulos were elected
as members of the Audit Committee.
·
Tuomo Pätsi was elected the Chair of the
Nomination Committee and Markku Jalkanen and Christine Roth were
elected as the other members of the Nomination
Committee.
·
John Poulos was elected as the Chair of the
Remuneration Committee and Tuomo Pätsi and Christine Roth were
elected as the other members of the Remuneration
Committee.
·
John Poulos was elected as the Chair of the
Business Development Committee and Markku Jalkanen and Juho
Jalkanen were elected as the other members of the Business
Development Committee
For
more information please contact:
Faron Pharmaceuticals
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Cairn Financial Advisers LLP,
Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213
0880
Peel Hunt LLP, Broker
Christopher Golden, James
Steel
Phone: +44 (0) 20 7418
8900
Sisu Partners Oy, Certified Adviser
on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555
4727
Jukka Järvelä
Phone: +358 (0)50 553
8990
About Faron Pharmaceuticals
Oy
Faron (AIM: FARN, First North:
FARON) is a global, clinical-stage biopharmaceutical company,
focused on tackling cancers via novel immunotherapies. Its mission
is to bring the promise of immunotherapy to a broader population by
uncovering novel ways to control and harness the power of the
immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical
trials as a potential therapy for patients with hematological
cancers in combination with other standard treatments treatments
and as a monotherapy in last line solid cancers. Further
information is available at www.faron.com.